×
About 15,210 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  3,791 results

Factors Associated With Adverse Outcomes in Uveitis Related to Spondyloarthritis: Devel...
https://doi.org/10.1097/RHU.0000000000001921
Journal of Clinical Rheumatology : Practical Reports on R... Sieiro Santos C, Sendino-Tenorio I et. al.

Feb 3rd, 2023 - Evaluating the efficacy and refractoriness to treatment and determining factors associated with adverse outcomes in uveitis associated with spondylarthritis (SpA) are complicated by the lack of validated outcome measures. The aims of this study we...

Diffuse posterior scleritis associated with HLA-B14* managed with multimodal imaging: c...
https://doi.org/10.1097/ICB.0000000000001373
Retinal Cases & Brief Reports; Raneri M, Fossataro F et. al.

Feb 3rd, 2023 - To report a case of posterior scleritis (PS) in an HLA-B*14 positive patient highlighting the crucial role of multimodal imaging and of autoimmune systemic disease screening for the diagnosis. Case Report. A 73-year-old woman, complaining of ocula...

Can a Nomogram Predict Survival After Treatment for an Ankylosing Spondylitis Cervical ...
https://doi.org/10.1097/CORR.0000000000002542
Clinical Orthopaedics and Related Research; Bai H, Li Y et. al.

Feb 3rd, 2023 - Ankylosing spondylitis-related cervical spine fracture with neurologic impairment (ASCF-NI) is a rare but often lethal injury. Factors independently associated with survival after treatment remain poorly defined, and identifying patients who are l...

ERAP1 and the return of the UPR in ankylosing spondylitis.
https://doi.org/10.1038/s41584-023-00910-y
Nature Reviews. Rheumatology; Haroon N, Inman RD

Feb 2nd, 2023 - ERAP1 and the return of the UPR in ankylosing spondylitis.|2023|Haroon N,Inman RD,|

Natural History and Development of Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT01422694

Jan 31st, 2023 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from ot...

see more →

Guidelines  11 results

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients ...
https://www.ncbi.nlm.nih.gov/pubmed/30717501
Pain Physician; Kaye AD, Manchikanti L et. al.

Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...

The effectiveness, safety, and economic evaluation of Korean medicine for unexplained i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779787
Medicine

Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
https://doi.org/10.1136/annrheumdis-2016-210770
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.

Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...

EULAR recommendations for cardiovascular disease risk management in patients with rheum...
https://doi.org/10.1136/annrheumdis-2016-209775
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.

Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...

see more →

Drugs  1,036 results see all →

Clinicaltrials.gov  389 results

Natural History and Development of Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT01422694

Jan 31st, 2023 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from ot...

Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
https://clinicaltrials.gov/ct2/show/NCT00056719

Jan 31st, 2023 - The susceptibility to ankylosing spondylitis (AS) is largely genetically determined. Recent studies suggest that the severity of AS is also influenced by genetic factors. The goal of this study is to identify genes that influence the severity of A...

Progression of Spinal Fusion in Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT00085995

Jan 31st, 2023 - Spinal fusion is the clinical, radiological, and pathological hallmark of ankylosing spondylitis (AS). However, spinal fusion occurs slowly in AS. Serial radiographs rarely show changes over 2 years, and often 5 or more years are needed to demonst...

BETY-BIOPSYCHOSOCIAL QUESTIONNAIRE IN PARTİCİPANTS RECEIVING RADIOTHERAPY
https://clinicaltrials.gov/ct2/show/NCT05213416

Jan 31st, 2023 - It is known that psycho-physiological processes affect the results of medical treatment in chronic diseases [1]. In oncological rehabilitation, the psychological, social and functional problems of individuals with cancer are considered together, a...

Effect of Exercise on Disease Activity in Patients With Ankylosing Spondylitis by SIRI and SII
https://clinicaltrials.gov/ct2/show/NCT05703932

Jan 30th, 2023 - Ankylosing spondylitis (AS) is an inflammatory disease of unknown etiology characterized by chronic inflammation of the sacroiliac joints, spine and paraspinal soft tissues. Extra-articular manifestations such as anterior uveitis, inflammatory bow...

see more →

News  831 results

PsA-related uveitis: Real-world data on epidemiology and clinical features
https://www.mdedge.com/rheumatology/article/260852/psoriatic-arthritis/psa-related-uveitis-real-world-data-epidemiology-and

Jan 26th, 2023 - Key clinical point: Uveitis related to psoriatic arthritis (PsA) had a prevalence of approximately 5%, presented as an acute and recurrent disease with anterior and unilateral involvement, and was associated with impaired quality of life and incre.

TNFi raises the risk for septic arthritis in seropositive RA
https://www.mdedge.com/rheumatology/article/260778/rheumatoid-arthritis/tnfi-raises-risk-septic-arthritis-seropositive-ra

Jan 24th, 2023 - Key clinical point: Tumor necrosis factor inhibitors (TNFi) increased the risk for septic arthritis in patients with seropositive rheumatoid arthritis (RA), with higher incidences within 1 year of initiating TNFi. Major finding: Patients with sero.

Phase III Trials Back Bimekizumab for Spondyloarthritis
https://www.medpagetoday.com/rheumatology/arthritis/102660

Jan 17th, 2023 - Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. With nearly 600 patients enrolled in two parallel phase III trials, 45% a...

Axial PsA: A distinct phenotype not to be confused with ankylosing spondylitis+psoriasis
https://www.mdedge.com/rheumatology/article/260157/psoriatic-arthritis/axial-psa-distinct-phenotype-not-be-confused

Dec 14th, 2022 - Key clinical point: Axial psoriatic arthritis (PsA) can be categorized as a distinct subtype of PsA because it exhibits clinical and radiological symptoms that are different from those of ankylosing spondylitis (AS) with psoriasis. Major finding:.

Xeljanz Cancer Risks Detailed
https://www.medpagetoday.com/rheumatology/generalrheumatology/102106

Dec 7th, 2022 - The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study. Tofacitinib at either 5 or 10 mg twice ...

see more →

Patient Education  26 results see all →